Antipsychotics for Bipolar Disorder Review | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Antipsychotics for Bipolar Disorder: Mania, Depression, Maintenance [ Medical Education ](https://mdster.com/blog?category=medical-education) Antipsychotics for Bipolar Disorder: Mania, Depression, Maintenance ===================================================================== A high-yield, board-focused guide to choosing antipsychotics across phases of bipolar illness without missing the metabolic price tag [ MDster Editorial Team ](https://mdster.com/about) · Jul 17, 2026 · 7 min read · 34 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Psychiatry ](https://mdster.com/blog?tag=psychiatry) [ Psychiatry Boards ](https://mdster.com/blog?tag=psychiatry-boards) [ Psychopharmacology ](https://mdster.com/blog?tag=psychopharmacology) [ Bipolar Disorder ](https://mdster.com/blog?tag=bipolar-disorder) [ Antipsychotics ](https://mdster.com/blog?tag=antipsychotics) [ Metabolic Monitoring ](https://mdster.com/blog?tag=metabolic-monitoring) ![Antipsychotics for Bipolar Disorder: Mania, Depression, Maintenance](https://mdster.com/storage/blog/images/antipsychotics-for-bipolar-disorder-mania-depression-maintenance.jpg) Share this article Share this post On this page 1. [ Think by phase, not by drug class ](#think-by-phase-not-by-drug-class) 2. [ Acute mania: stop the fire first ](#acute-mania-stop-the-fire-first) 3. [ Bipolar depression approvals: much narrower than trainees think ](#bipolar-depression-approvals-much-narrower-than-trainees-think) 4. [ Maintenance: avoid therapeutic inertia ](#maintenance-avoid-therapeutic-inertia) 5. [ Metabolic monitoring is part of the prescription ](#metabolic-monitoring-is-part-of-the-prescription) 6. [ Clinical correlations ](#clinical-correlations) 7. [ Key Takeaways ](#key-takeaways) 8. [ Conclusion ](#conclusion) 9. [ Frequently Asked Questions ](#blog-faqs) 10. [ References ](#references-heading) On this page 1. [ Think by phase, not by drug class ](#think-by-phase-not-by-drug-class) 2. [ Acute mania: stop the fire first ](#acute-mania-stop-the-fire-first) 3. [ Bipolar depression approvals: much narrower than trainees think ](#bipolar-depression-approvals-much-narrower-than-trainees-think) 4. [ Maintenance: avoid therapeutic inertia ](#maintenance-avoid-therapeutic-inertia) 5. [ Metabolic monitoring is part of the prescription ](#metabolic-monitoring-is-part-of-the-prescription) 6. [ Clinical correlations ](#clinical-correlations) 7. [ Key Takeaways ](#key-takeaways) 8. [ Conclusion ](#conclusion) 9. [ Frequently Asked Questions ](#blog-faqs) 10. [ References ](#references-heading) A patient with bipolar I mania who has not slept for 4 nights does not need a lecture on receptor binding. They need an antipsychotic that will calm mania quickly, a maintenance plan that survives discharge, and a psychiatrist who remembers that the drug that fixes today’s crisis may create next year’s diabetes. In bipolar disorder, antipsychotics are phase-specific tools, not interchangeable sedatives. [\[1\]](#cite-1 "Reference [1]") Think by phase, not by drug class --------------------------------- Start with three questions: Is the target **mania**, **bipolar depression**, or **maintenance**? Then ask a fourth question that trainees forget: what is the long-term adverse effect phenotype for this specific patient? Boards love this distinction because the same drug is not equally useful across all phases. [\[1\]](#cite-1 "Reference [1]") Quetiapine is the classic example of breadth. It has evidence or labeling across acute mania, bipolar depression, and maintenance pathways, whereas lurasidone is a bipolar depression drug, not an antimanic drug, and olanzapine is effective but metabolically expensive. If you keep that mental model, most prescribing questions get easier. [\[2\]](#cite-2 "Reference [2]") Acute mania: stop the fire first -------------------------------- For acute mania, the 2023 VA/DoD guideline suggests **lithium or quetiapine** as monotherapy first, then **olanzapine, paliperidone, or risperidone** if those are not selected, with additional alternatives including **aripiprazole, asenapine, cariprazine, and ziprasidone**. For breakthrough mania or inadequate response on monotherapy, it suggests combining **lithium or valproate** with **haloperidol, asenapine, quetiapine, olanzapine, or risperidone**. [\[1\]](#cite-1 "Reference [1]") That is the clinical lesson: in true mania, choose drugs with clear antimanic efficacy and do not overvalue theoretical antidepressant properties. If the patient is psychotic, dangerous, or rapidly escalating, prioritize fast antimanic control, route flexibility, and the likelihood that the patient will still take the drug after discharge. That last point is why quetiapine and olanzapine remain common despite their baggage. [\[1\]](#cite-1 "Reference [1]") A useful exam pitfall: do **not** assume that every SGA is a good add-on after lithium or valproate failure. VA/DoD specifically suggests **against** adding aripiprazole, paliperidone, or ziprasidone after unsatisfactory response to lithium or valproate monotherapy for acute mania. [\[1\]](#cite-1 "Reference [1]") As of **February 20, 2026**, **milsaperidone (Bysanti)** joined the FDA-approved adult options for **acute manic or mixed episodes associated with bipolar I disorder**. It matters for being current, but it is not yet a board staple; for now, know it as a newer mania-only atypical with QTc cautions. [\[3\]](#cite-3 "Reference [3]") > **Clinical Pearl:** In bipolar mania, do not ask, “Which antipsychotic is nicest?” Ask, “Which one will stop mania now, and can I live with its long-term burden?” [\[1\]](#cite-1 "Reference [1]") Bipolar depression approvals: much narrower than trainees think --------------------------------------------------------------- As of **July 17, 2026**, the adult FDA-approved antipsychotic-based options for bipolar depression are: **quetiapine** monotherapy; **lurasidone** as monotherapy or adjunctive therapy with lithium or valproate for **bipolar I** depression; **cariprazine** for **bipolar I** depression; **lumateperone** as monotherapy or adjunctive therapy with lithium or valproate for **bipolar I or II** depression; and **olanzapine-fluoxetine combination** for **bipolar I** depression. [\[2\]](#cite-2 "Reference [2]") The nuance that gets tested is this: **olanzapine alone** appears in VA/DoD as a suggested monotherapy option for acute bipolar depression, but the FDA-labeled olanzapine-based depression product is **olanzapine-fluoxetine**, not olanzapine monotherapy. Another trap: **lurasidone is not approved for mania**, and its labeling emphasizes administration **with food** to ensure absorption. [\[1\]](#cite-1 "Reference [1]") If you want one practical workhorse, quetiapine is still the broadest antipsychotic across bipolar phases. Its label includes acute mania, depressive episodes associated with bipolar disorder, and maintenance as an adjunct to lithium or divalproex. [\[2\]](#cite-2 "Reference [2]") Maintenance: avoid therapeutic inertia -------------------------------------- Maintenance is where many clinicians make their biggest mistake: they simply continue the discharge regimen forever. VA/DoD recommends **lithium or quetiapine** for prevention of recurrent mania; if those are not suitable, it suggests **oral olanzapine, oral paliperidone, or risperidone LAI**. For recurrent mania despite a mood stabilizer, it suggests adding **aripiprazole, olanzapine, quetiapine, or ziprasidone** to lithium or valproate. [\[1\]](#cite-1 "Reference [1]") For depressive recurrence, the relevant antipsychotic combinations are narrower. VA/DoD suggests **olanzapine, lurasidone, or quetiapine** combined with lithium or valproate for prevention of recurrent bipolar depressive episodes. Read that carefully: it is a **guideline-supported strategy**, but not every one of these drugs carries a matching FDA maintenance indication. [\[1\]](#cite-1 "Reference [1]") When nonadherence drives relapse, think LAI early instead of as a last-ditch move. **Aripiprazole Maintena** is FDA-approved for **maintenance monotherapy** in bipolar I disorder, while **Risperdal Consta** is approved for **maintenance monotherapy or adjunctive therapy** with lithium or valproate in bipolar I disorder. [\[4\]](#cite-4 "Reference [4]") Metabolic monitoring is part of the prescription ------------------------------------------------ The drug choice is not just about efficacy. VA/DoD’s adverse-effect table places **olanzapine** highest for weight gain and metabolic burden, **quetiapine** in an intermediate-high zone, and **aripiprazole, asenapine, cariprazine, and lurasidone** lower; **ziprasidone** looks lighter metabolically but carries the strongest QTc signal in that table. [\[1\]](#cite-1 "Reference [1]") Do not tell patients a drug is “weight neutral” unless you are willing to defend that statement. VA/DoD recommends metabolic monitoring with **BMI at baseline, 1, 2, 3, and 6 months, then annually**, and **HbA1c, fasting plasma glucose, and fasting lipid panel at baseline, 3 months, and annually**. APA also emphasizes ongoing monitoring of neurologic, cardiovascular, and metabolic adverse effects during antipsychotic treatment. [\[1\]](#cite-1 "Reference [1]") ### Clinical correlations - If the patient has severe mania **and** obesity, prediabetes, or prior antipsychotic weight gain, do not default blindly to olanzapine; reserve it for when its efficacy or prior response clearly justifies the metabolic tradeoff. [\[1\]](#cite-1 "Reference [1]") - If the patient has **bipolar depression with insomnia**, quetiapine often fits both syndrome and evidence better than lurasidone. [\[1\]](#cite-1 "Reference [1]") - If the patient keeps relapsing because they stop oral medication, move the adherence problem to the center of treatment planning and consider an LAI. [\[4\]](#cite-4 "Reference [4]") Key Takeaways ------------- - Match the antipsychotic to the **phase** of illness, not just the diagnosis of bipolar disorder. [\[1\]](#cite-1 "Reference [1]") - **Quetiapine** has the broadest practical footprint across mania, bipolar depression, and maintenance pathways. [\[2\]](#cite-2 "Reference [2]") - Bipolar depression approvals are narrower: know the difference between **quetiapine, lurasidone, cariprazine, lumateperone, and olanzapine-fluoxetine**. [\[5\]](#cite-5 "Reference [5]") - For maintenance, use **combination strategies** when recurrence breaks through a mood stabilizer, and think **LAI** when adherence is the real illness amplifier. [\[1\]](#cite-1 "Reference [1]") - Metabolic monitoring is not paperwork. It is part of safe bipolar prescribing. [\[1\]](#cite-1 "Reference [1]") Conclusion ---------- The right antipsychotic in bipolar disorder is the one that matches polarity, relapse pattern, and patient risk. Prescribe with the next 12 months in mind, not just the next 12 hours. [\[1\]](#cite-1 "Reference [1]") Frequently Asked Questions ---------------------------- ### Is lurasidone a mania drug in bipolar disorder? No. Lurasidone is FDA-labeled for **bipolar I depression** as monotherapy and as adjunctive therapy with lithium or valproate, but its efficacy for mania has not been established. It should also be taken with food. [\[5\]](#cite-5 "Reference [5]") ### Which antipsychotic has the broadest practical role across bipolar phases? **Quetiapine** is the best single answer. It has labeling for acute mania, bipolar depressive episodes, and maintenance treatment as an adjunct to lithium or divalproex, and guideline support across recurrence prevention. [\[2\]](#cite-2 "Reference [2]") ### When should I think about an LAI for bipolar I disorder? Think about an LAI when relapse is being driven by nonadherence rather than lack of drug efficacy. FDA-approved maintenance options include **aripiprazole Maintena** as monotherapy and **risperidone Consta** as monotherapy or adjunctive therapy with lithium or valproate. [\[4\]](#cite-4 "Reference [4]") ### Does olanzapine alone have an FDA approval for bipolar depression? Not in the way many trainees assume. The FDA-approved olanzapine-based depression product is **olanzapine-fluoxetine combination** for bipolar I depression, although VA/DoD also lists olanzapine monotherapy as a suggested evidence-based option for acute bipolar depression. [\[6\]](#cite-6 "Reference [6]") ### What metabolic monitoring schedule should I remember for board exams and clinic? A practical high-yield schedule is: **BMI** at baseline, 1, 2, 3, and 6 months, then annually; **HbA1c, fasting glucose, and fasting lipids** at baseline, 3 months, and annually, with ongoing clinical monitoring for EPS, tardive dyskinesia, BP, and other adverse effects. [\[1\]](#cite-1 "Reference [1]") References (10) ------------------- 1. 1. [ VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder, 2023 ](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/bd/VA-DOD-CPG-BD-Full-CPGFinal508.pdf) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ SEROQUEL (quetiapine) tablets, Highlights of Prescribing Information, FDA ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020639s072lbl.pdf) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ www.accessdata.fda.gov/drugsatfda\_docs/label/2026/220358Orig1s000lbl.pdf ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220358Orig1s000lbl.pdf) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ ABILIFY MAINTENA (aripiprazole) extended-release injectable suspension, Highlights of Prescribing Information, FDA, 2026 ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202971s018%2C217006s001lbl.pdf) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ LATUDA (lurasidone hydrochloride) tablets, Official Label, DailyMed ](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ SYMBYAX (olanzapine and fluoxetine) capsules for oral use, FDA ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021520s054lbl.pdf) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ VRAYLAR (cariprazine) capsules, Highlights of Prescribing Information, FDA ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204370s012lbl.pdf) 8. 8. [ CAPLYTA (lumateperone) capsules, Highlights of Prescribing Information, FDA, 2026 ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209500s017lbl.pdf) 9. 9. [ RISPERDAL CONSTA (risperidone) long-acting injection, Highlights of Prescribing Information, FDA ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021346s052Lbl.pdf) 10. 10. [ ZYPREXA (olanzapine) Highlights of Prescribing Information, FDA, 2025 ](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020592s077%2C021086s050%2C021253s047s066lbl.pdf) Keep going Build momentum in Psychiatry with a focused study pathway ----------------------------------------------------------- - Exam‑style questions for Psychiatry - Smart review to target weak topics - Progress tracking that keeps you accountable [ Start your free trial ](https://mdster.com/user/dashboard) [ Explore Psychiatry ](https://mdster.com/speciality/psychiatry) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Psychiatry ](https://mdster.com/blog?tag=psychiatry) [ # Psychiatry Boards ](https://mdster.com/blog?tag=psychiatry-boards) [ # Psychopharmacology ](https://mdster.com/blog?tag=psychopharmacology) [ # Bipolar Disorder ](https://mdster.com/blog?tag=bipolar-disorder) [ # Antipsychotics ](https://mdster.com/blog?tag=antipsychotics) [ # Metabolic Monitoring ](https://mdster.com/blog?tag=metabolic-monitoring) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Genital Tract Lacerations and Hematomas in PPH: Hidden Hemorrhage 6 min read Jul 16, 2026 ](https://mdster.com/blog/genital-tract-lacerations-and-hematomas-in-pph-hidden-hemorrhage) [### Adolescent Confidentiality and Risk Prevention in Family Medicine 7 min read Jul 15, 2026 ](https://mdster.com/blog/adolescent-confidentiality-and-risk-prevention-in-family-medicine) [### Tumor Lysis Syndrome Risk Assessment: Spot the Patient at Risk 7 min read Jul 14, 2026 ](https://mdster.com/blog/tumor-lysis-syndrome-risk-assessment-spot-the-patient-at-risk) Related Posts ------------- [ ![Genital Tract Lacerations and Hematomas in PPH: Hidden Hemorrhage](https://mdster.com/storage/blog/images/genital-tract-lacerations-and-hematomas-in-pph-hidden-hemorrhage.jpg) Medical Education ### Genital Tract Lacerations and Hematomas in PPH: Hidden Hemorrhage A high-yield review of postpartum genital tract lacerations and hematomas: recognize occult bleeding early, repair tears properly, and escalate to OR or imaging at the right time. 6 min read 0 comments ](https://mdster.com/blog/genital-tract-lacerations-and-hematomas-in-pph-hidden-hemorrhage) [ ![Adolescent Confidentiality and Risk Prevention in Family Medicine](https://mdster.com/storage/blog/images/adolescent-confidentiality-and-risk-prevention-in-family-medicine.jpg) Medical Education ### Adolescent Confidentiality and Risk Prevention in Family Medicine A practical, board-focused guide to adolescent confidentiality, injury prevention, sexual health, substance use, and mental health screening in Family Medicine. 7 min read 0 comments ](https://mdster.com/blog/adolescent-confidentiality-and-risk-prevention-in-family-medicine) [ ![Tumor Lysis Syndrome Risk Assessment: Spot the Patient at Risk](https://mdster.com/storage/blog/images/tumor-lysis-syndrome-risk-assessment-spot-the-patient-at-risk.jpg) Medical Education ### Tumor Lysis Syndrome Risk Assessment: Spot the Patient at Risk A focused Internal Medicine review of TLS risk assessment, with high-yield emphasis on renal dysfunction, tumor burden, chemosensitivity, and high-risk leukemias/lymphomas. 7 min read 0 comments ](https://mdster.com/blog/tumor-lysis-syndrome-risk-assessment-spot-the-patient-at-risk) [ ![How to Prepare for the UEMS Section of Psychiatry (European Board Examination in Psychiatry (EBEP))](https://mdster.com/storage/blog/images/how-to-prepare-for-the-uems-section-of-psychiatry-european-board-examination-in-psychiatry.jpg) Study Tips ### How to Prepare for the UEMS Section of Psychiatry (European Board Examination in Psychiatry (EBEP)) Preparing for the EBEP? This guide shows busy psychiatry doctors how to use the official blueprint, timed vignette practice, and smart revision blocks to study efficiently. 5 min read 0 comments ](https://mdster.com/blog/how-to-prepare-for-the-uems-section-of-psychiatry-european-board-examination-in-psychiatry) [ ![Precocious and Delayed Puberty: Bone Age, Patterns, Referral](https://mdster.com/storage/blog/images/precocious-and-delayed-puberty-bone-age-patterns-referral.jpg) Medical Education ### Precocious and Delayed Puberty: Bone Age, Patterns, Referral A board-focused pediatrics review of how bone age, growth velocity, and pubertal pattern separate central from peripheral causes—and when endocrine referral should be urgent. 7 min read 0 comments ](https://mdster.com/blog/precocious-and-delayed-puberty-bone-age-patterns-referral) [ ![ARDS Adjuncts: Proning, Paralysis, and Inhaled Vasodilators](https://mdster.com/storage/blog/images/ards-adjuncts-proning-paralysis-and-inhaled-vasodilators.jpg) Medical Education ### ARDS Adjuncts: Proning, Paralysis, and Inhaled Vasodilators Focused review of ARDS adjuncts for refractory hypoxemia: when prone positioning changes outcomes, when neuromuscular blockade helps, and why inhaled vasodilators mostly buy time. 4 min read 0 comments ](https://mdster.com/blog/ards-adjuncts-proning-paralysis-and-inhaled-vasodilators) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept